Dow Louise F, Case Alfie M, Paustian Megan P, Pinkerton Braeden R, Simeon Princess, Trippier Paul C
Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center Omaha NE 68106 USA
Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center Omaha NE 68106 USA.
RSC Med Chem. 2023 Sep 22;14(11):2206-2230. doi: 10.1039/d3md00399j. eCollection 2023 Nov 15.
There is a myriad of enzymes within the body responsible for maintaining homeostasis by providing the means to convert substrates to products as and when required. Physiological enzymes are tightly controlled by many signaling pathways and their products subsequently control other pathways. Traditionally, most drug discovery efforts focus on identifying enzyme inhibitors, due to upregulation being prevalent in many diseases and the existence of endogenous substrates that can be modified to afford inhibitor compounds. As enzyme downregulation and reduction of endogenous activators are observed in multiple diseases, the identification of small molecules with the ability to activate enzymes has recently entered the medicinal chemistry toolbox to afford chemical probes and potential therapeutics as an alternative means to intervene in diseases. In this review we highlight the progress made in the identification and advancement of non-kinase enzyme activators and their potential in treating various disease states.
体内存在无数种酶,它们通过提供在需要时将底物转化为产物的方式来维持体内平衡。生理酶受到许多信号通路的严格控制,其产物随后控制其他通路。传统上,大多数药物研发工作都集中在鉴定酶抑制剂上,这是因为在许多疾病中上调现象普遍存在,并且存在可以被修饰以提供抑制剂化合物的内源性底物。由于在多种疾病中观察到酶下调和内源性激活剂减少,最近能够激活酶的小分子的鉴定已进入药物化学工具库,以提供化学探针和潜在的治疗方法,作为干预疾病的另一种手段。在这篇综述中,我们重点介绍了在非激酶酶激活剂的鉴定和开发方面取得的进展及其在治疗各种疾病状态方面的潜力。